Watch and Wait vs Gamma Knife: When to Monitor a Benign Tumour and When to Treat

Watch and wait means monitoring a small, slow-growing benign brain tumour with regular MRI scans instead of treating it straight away, and switching to Gamma Knife radiosurgery when the tumour is shown to be growing or is causing new or worsening symptoms. It is the standard first approach for many small acoustic neuromas and grade I meningiomas, because these tumours often grow slowly or not at all, and treatment can be timed to the moment it is actually needed¹.

When my acoustic neuroma was found, the first thing my consultant said was not “we will treat this”, it was “we will watch it”. I remember feeling almost cheated, as if being handed a diagnosis and then told to go home and wait was the worst of both worlds. It took me a while to understand that surveillance is a deliberate, evidence-based plan, not indecision, and that the point of watching was to earn the timing of treatment rather than to avoid it. This is the article I wanted then: what watching actually involves, and where the line to Gamma Knife radiosurgery is drawn.

What does watch and wait mean?

Watch and wait, also called active surveillance, means keeping a benign tumour under regular MRI review rather than treating it, on the understanding that many small acoustic neuromas and meningiomas change slowly or stay stable for years. It is an active plan with scheduled scans and clinic visits, not a decision to ignore the tumour. The logic is straightforward: radiosurgery and surgery both carry their own risks, so if a tumour is small, benign, and not causing trouble, there is often no benefit in treating it before it declares whether it will grow at all¹.

The reason this works for these particular tumours is that they are benign and slow. A grade I meningioma and an acoustic neuroma are not cancers that spread; the question is only whether the target enlarges enough to threaten hearing, balance, or nearby structures. For the wider set of options in acoustic neuroma specifically, see acoustic neuroma treatment options.

How does surveillance actually work?

Surveillance works by comparing serial MRI scans over time to measure whether the tumour is growing, alongside checks of your symptoms such as hearing. A common pattern is a baseline scan at diagnosis, a second at around 6 to 12 months to establish the growth rate, then yearly scans that can space out if the tumour stays stable. Any new symptom, such as a drop in hearing on one side or worsening balance, usually brings the next scan forward.

What the scans are looking for is a trend, not a single measurement. One image cannot tell you whether a tumour is growing; two or three across time can. In my own case the scans were the hardest part, because each one reopened the question I wanted closed. That waiting between scans has a name and a shape of its own, which I have written about in radiosurgery and scanxiety. The clinical value of the schedule, though, is real: it is what lets a team offer radiosurgery at the right time rather than too early.

When do you switch to Gamma Knife?

The usual trigger to move from watching to Gamma Knife is documented growth across two or more scans, or new or worsening symptoms, rather than reaching a fixed size on the first scan. Growth on serial imaging is the clearest signal, because it shows the tumour is not one of the stable ones. New or progressing symptoms, such as declining hearing, tinnitus, balance problems, or facial numbness, are the other main trigger. Size and position feed in as well: teams often prefer to act while the target is still comfortably within the single-session range, around 3 to 3.5 cm or smaller (about 10 to 15 cc in volume), because that is where control is high and the dose to healthy tissue is easiest to keep low².

There is a specific reason not to wait too long with an acoustic neuroma: hearing. Hearing preservation after radiosurgery varies widely, roughly 40 to 80%, and it depends on tumour size and on how good your hearing is at the time of treatment³. Treating while the tumour is small and hearing is still serviceable tends to give the better chance of keeping it. This is exactly why surveillance is monitored closely rather than casually: the aim is to catch the moment where treating now beats waiting. Whether a given target actually qualifies is set out in am I a candidate for Gamma Knife.

What does Gamma Knife offer for a benign tumour?

For a small benign tumour, Gamma Knife aims for long-term control, meaning the tumour stops growing, rather than disappearance, and the control rates are high. For acoustic neuroma, 5-year tumour control is roughly 90 to 99%, with a margin dose most commonly 12 to 13 Gy, and facial-nerve preservation of about 95 to 100% at 5 years³. For a benign grade I meningioma, 5-year local control is roughly 85 to 100%, with a median around 94%; control is markedly worse for the less common grade II and III meningiomas, which is one reason the diagnosis and grade matter so much⁴.

The catch that surprises people, and surprised me, is that control is not the same as the tumour vanishing. The target usually stays visible on follow-up scans; benign tumours change slowly over 1 to 3 years, and the goal is that they stop growing. For how that plays out over the scans that follow treatment, see Gamma Knife results and follow-up. For the treatment day and dose themselves, see Gamma Knife for acoustic neuroma and Gamma Knife for meningioma.

Watching versus treating: how the trade-offs compare

The trade-off is between the risks and downsides of surveillance (the chance of growth or symptom change between scans, and the strain of waiting) and the risks of treating now (a high dose of radiation and its side effects) applied to a tumour that might never have needed it. Watching avoids treatment entirely for the many people whose tumour stays stable, at the cost of ongoing scans and the possibility of missing a window if growth is fast. Treating removes that uncertainty and locks in high control, but commits you to a procedure and its delayed effects, chiefly radiation necrosis at roughly 5 to 25% depending on size and dose⁴.

This is genuinely a decision made by a multidisciplinary team looking at your imaging over time, not something a website or a single number can settle⁵. My own team watched for a period, saw growth, and only then recommended radiosurgery, and understanding that sequence made the eventual treatment far easier to accept. The comparison with the other main path, open microsurgery, is set out in Gamma Knife versus surgery, and the emotional side of holding a diagnosis while you wait is in the emotional side of a brain tumour diagnosis.